These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 37158911)

  • 21. Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study.
    Ochs-Ross R; Wajs E; Daly EJ; Zhang Y; Lane R; Lim P; Drevets WC; Steffens DC; Sanacora G; Jamieson C; Hough D; Manji H; Singh JB
    Am J Geriatr Psychiatry; 2022 May; 30(5):541-556. PubMed ID: 34750057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant in Adult Patients with Treatment-Resistant Depression: A Randomized, Double-Blind, Multicenter, Active-Controlled Study Conducted in China and USA.
    Chen X; Hou X; Bai D; Lane R; Zhang C; Canuso C; Wang G; Fu DJ
    Neuropsychiatr Dis Treat; 2023; 19():693-707. PubMed ID: 37025256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Factors Influencing Depression Endpoints Research (FINDER) study: final results of Italian patients with depression.
    Caruso R; Rossi A; Barraco A; Quail D; Grassi L;
    Ann Gen Psychiatry; 2010 Jul; 9():33. PubMed ID: 20670396
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment response to esketamine nasal spray in patients with major depressive disorder and acute suicidal ideation or behavior without evidence of early response: a pooled post hoc analysis of ASPIRE.
    Turkoz I; Lopena O; Salvadore G; Sanacora G; Shelton R; Fu DJ
    CNS Spectr; 2023 Aug; 28(4):482-488. PubMed ID: 35904046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health-related quality of life of long-term patients receiving opioid agonist therapy: a nested prospective cohort study in Norway.
    Aas CF; Vold JH; Skurtveit S; Lim AG; Ruths S; Islam K; Askildsen JE; Løberg EM; Fadnes LT; Johansson KA;
    Subst Abuse Treat Prev Policy; 2020 Sep; 15(1):68. PubMed ID: 32883319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Self-reported review of the value of esketamine in patients with treatment-resistant depression: Understanding the patient experience in the STRIVE Study.
    Starr HL; Abell J; Larish A; Lewis S; DeMuro C; Gogate J; Jamieson C; Daly E; Zaki N; Kramer M
    Psychiatry Res; 2020 Nov; 293():113376. PubMed ID: 32818917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
    Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB
    Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II).
    Ionescu DF; Fu DJ; Qiu X; Lane R; Lim P; Kasper S; Hough D; Drevets WC; Manji H; Canuso CM
    Int J Neuropsychopharmacol; 2021 Jan; 24(1):22-31. PubMed ID: 32861217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program.
    Doherty T; Wajs E; Melkote R; Miller J; Singh JB; Weber MA
    CNS Drugs; 2020 Mar; 34(3):299-310. PubMed ID: 31994024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Appraising esketamine nasal spray for the management of treatment-resistant depression in adults: Number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Citrome L; DiBernardo A; Singh J
    J Affect Disord; 2020 Jun; 271():228-238. PubMed ID: 32479321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health-related quality of life measured using the EQ-5D-5L: South Australian population norms.
    McCaffrey N; Kaambwa B; Currow DC; Ratcliffe J
    Health Qual Life Outcomes; 2016 Sep; 14(1):133. PubMed ID: 27644755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neurofeedback Treatment on Depressive Symptoms and Functional Recovery in Treatment-Resistant Patients with Major Depressive Disorder: an Open-Label Pilot Study.
    Lee YJ; Lee GW; Seo WS; Koo BH; Kim HG; Cheon EJ
    J Korean Med Sci; 2019 Nov; 34(42):e287. PubMed ID: 31674161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association Between Myasthenia Gravis-Activities of Daily Living (MG-ADL) and EQ-5D-5L Utility Values: The Additional Effect of Efgartigimod on Utilities.
    Dewilde S; Qi CZ; Phillips G; Iannazzo S; Janssen MF
    Adv Ther; 2023 Apr; 40(4):1818-1829. PubMed ID: 36867327
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characteristics of Real-world Commercially Insured Patients With Treatment-resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United States.
    Karkare S; Zhdanava M; Pilon D; Nash AI; Morrison L; Shah A; Lefebvre P; Joshi K
    Clin Ther; 2022 Nov; 44(11):1432-1448. PubMed ID: 36207167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of Clinical Global Impressions-Severity (CGI-S) to Assess Response to Antidepressant Treatment in Patients with Treatment-Resistant Depression.
    Morrens J; Mathews M; Popova V; Borentain S; Rive B; Gonzalez Martin Moro B; Jamieson C; Zhang Q
    Neuropsychiatr Dis Treat; 2022; 18():1127-1132. PubMed ID: 35707064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study.
    Zaki N; Chen LN; Lane R; Doherty T; Drevets WC; Morrison RL; Sanacora G; Wilkinson ST; Popova V; Fu DJ
    Neuropsychopharmacology; 2023 Jul; 48(8):1225-1233. PubMed ID: 37173512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study.
    Chiappini S; d'Andrea G; De Filippis S; Di Nicola M; Andriola I; Bassetti R; Barlati S; Pettorruso M; Sensi S; Clerici M; Dell'Osso B; Vita A; Martinotti G
    Eur Neuropsychopharmacol; 2023 Sep; 74():15-21. PubMed ID: 37148637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I).
    Fu DJ; Ionescu DF; Li X; Lane R; Lim P; Sanacora G; Hough D; Manji H; Drevets WC; Canuso CM
    J Clin Psychiatry; 2020 May; 81(3):. PubMed ID: 32412700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigating the Effectiveness and Tolerability of Intranasal Esketamine Among Older Adults With Treatment-Resistant Depression (TRD): A Post-hoc Analysis from the REAL-ESK Study Group.
    d'Andrea G; Chiappini S; McIntyre RS; Stefanelli G; Carullo R; Andriola I; Zanardi R; Martiadis V; Sensi SL; Sani G; Clerici M; Di Lorenzo G; Vita A; Pettorruso M; Martinotti G
    Am J Geriatr Psychiatry; 2023 Dec; 31(12):1032-1041. PubMed ID: 37479669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Health-related quality of life, functional impairment and comorbidity in people with mild-to-moderate chronic kidney disease: a cross-sectional study.
    Fraser SD; Barker J; Roderick PJ; Yuen HM; Shardlow A; Morris JE; McIntyre NJ; Fluck RJ; McIntyre CW; Taal MW
    BMJ Open; 2020 Aug; 10(8):e040286. PubMed ID: 32764092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.